The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann

ROCHE HOLDING AG-BR signed a drug-discovery partnership with Atavistik Bio worth up to $2B on Thursday afternoon. The deal focuses on developing oral treatments for cardiovascular, kidney, and metabolic diseases. The agreement spans multiple targets and includes $70M upfront alongside $1.9B in milestone payments.